WHO ICTRP trial
A clinical study of chimeric-antigen-receptor T cells in the treatment of…
ChiCTR-OIH-17012645 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OIH-17012645 |
|---|---|
| Public title | A clinical study of chimeric-antigen-receptor T cells in the treatment of chemo-refractory or relapsing leukemia |
| Scientific title | A clinical study of chimeric-antigen-receptor T cells in the treatment of chemo-refractory or relapsing B cell acute lymphoblastic leukemia/NHL |
| Primary sponsor | Pediatrics of Nanfang hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | I (Phase I study) |
| Countries | China |
| Conditions | B cell acute lymphoblastic leukemia/NHL |
| Interventions | Case series:CD19-sepecific chimeric antigen receptor T cells (BG-T19) |
| Registration date | Sep 12, 2017 |
| Target size | Case series:22 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: